Tumor-mediated down-regulation of MHC class II in DC development is attributable to the epigenetic control of the CIITA type I promoter

European Journal of Immunology

Volumn 39, Issue 3, 2009, Pages 858-868

  Choi, Young Eun ^a   Yu, Ha Nul ^a   Yoon, Cheol Hee ^a   Bae, Yong Soo ^a  

^a Sungkyunkwan University   (South Korea)

Author keywords

DC differentiation; Epigenetic control; IL 10; Tumor microenvironments; Type 1 CTIIA down regulation

Indexed keywords

B7 ANTIGEN; CD14 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; GLYCOPROTEIN P 15095; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTONE H3; HISTONE H4; INTERLEUKIN 10; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; ONCOPROTEIN; PROTEIN CIITA; STAT5 PROTEIN; UNCLASSIFIED DRUG; HISTONE; HLA ANTIGEN CLASS 2; MHC CLASS II TRANSACTIVATOR PROTEIN; NUCLEAR PROTEIN; TRANSACTIVATOR PROTEIN;

ACETYLATION; ANIMAL CELL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; DOWN REGULATION; EPIGENETICS; FEMALE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE LOCUS; MAJOR HISTOCOMPATIBILITY COMPLEX; MICROENVIRONMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR IMMUNOLOGY; ANIMAL; BAGG ALBINO MOUSE; CULTURE MEDIUM; DRUG ANTAGONISM; DRUG EFFECT; GENETIC EPIGENESIS; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; NEOPLASM; TUMOR CELL LINE;

ANIMALS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CULTURE MEDIA, CONDITIONED; DENDRITIC CELLS; DOWN-REGULATION; EPIGENESIS, GENETIC; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HISTONES; HUMANS; INTERLEUKIN-10; MICE; MICE, INBRED BALB C; NEOPLASMS; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; STAT5 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS;

EID: 64049104441     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.200838674     Document Type: Article

References (45)

1. Almand, B., Resser, J. R., Lindman, B., Nadaf, S., Clark, J. I., Kwon, E. D., Carbone, D. P. and Gabrilovich, D. I., Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res. 2000. 6: 1755-1766.
2. Waldburger, J. M., Masternak, K., Muhlethaler-Mottet, A., Villard, J., Peretti, M., Landmann, S. and Reith, W., Lessons from the bare lymphocyte syndrome: Molecular mechanisms regulating MHC class II expression. Immunol. Rev. 2000. 178: 148-165.
3. Reith, W., LeibundGut-Landmann, S. and Waldburger, J. M., Regulation of MHC class II gene expression by the class II transactivator. Nat. Rev. Immunol. 2005. 5: 793-806.
4. Otten, L. A., Steimle, V., Bontron, S. and Mach, B., Quantitative control of MHC class II expression by the transactivator CIITA. Eur. J. Immunol. 1998. 28: 473-478.
5. Chang, C. H. and Flavell, R. A., Class II transactivator regulates the expression ofmultiple genes involved in antigen presentation. J. Exp. Med. 1995. 181: 765-767.
6. Chang, C. H., Guerder, S., Hong, S. C., van Ewijk, W. and Flavell, R. A., Mice lacking the MHC class II transactivator (CIITA) show tissue-specific impairment of MHC class II expression. Immunity 1996. 4: 167-178.
7. Muhlethaler-Mottet, A., Otten, L. A., Steimle, V. and Mach, B., Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J. 1997. 16: 2851-2860.
8. Pai, R. K., Askew, D., Boom,W. H. and Harding, C. V., Regulation of class II MHC expression in APCs: Roles of types I, III, and IV class II transactivator. J. Immunol. 2002. 169: 1326-1333.
9. LeibundGut-Landmann, S., Waldburger, J. M., Reis e Sousa, C., Acha-Orbea, H. and Reith, W., MHC class II expression is differentially regulated in plasmacytoid and conventional dendritic cells. Nat. Immunol. 2004. 5: 899-908.
10. Guermonprez, P., Valladeau, J., Zitvogel, L., Thery, C. and Amigorena, S., Antigen presentation and T cell stimulation by dendritic cells. Annu. Rev. Immunol. 2002. 20: 621-667.
11. Brown, R. D., Pope, B., Murray, A., Esdale, W., Sze, D. M., Gibson, J., Ho, P. J. et al., Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood 2001. 98: 2992-2998.
12. Ratta, M., Fagnoni, F., Curti, A., Vescovini, R., Sansoni, P., Oliviero, B., Fogli, M. et al., Dendritic cells are functionally defective in multiple myeloma: The role of interleukin-6. Blood 2002. 100: 230-237.
13. Sombroek, C. C., Stam, A. G., Masterson, A. J., Lougheed, S. M., Schakel, M. J., Meijer, C. J., Pinedo, H. M. et al., Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J. Immunol. 2002. 168: 4333-4343.
14. Gabrilovich, D., Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 2004. 4: 941-952.
15. Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D. and Carbone, D. P., Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 1996. 2: 1096-1103.
16. Gabrilovich, D. I., Corak, J., Ciernik, I. F., Kavanaugh, D. and Carbone, D. P., Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin. Cancer Res. 1997. 3: 483-490.
17. Masternak, K., Muhlethaler-Mottet, A., Villard, J., Zufferey, M., Steimle, V. and Reith, W., CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex. Genes Dev. 2000. 14: 1156-1166.
18. Serafini, P., Borrello, I. and Bronte, V., Myeloid suppressor cells in cancer: Recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. Cancer Biol. 2006. 16: 53-65.
19. Bellone, G., Carbone, A., Smirne, C., Scirelli, T., Buffolino, A., Novarino, A., Stacchini, A. et al., Cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells. J. Immunol. 2006. 177: 3448-3460.
20. Landmann, S., Muhlethaler-Mottet, A., Bernasconi, L., Suter, T., Waldburger, J. M., Masternak, K., Arrighi, J. F. et al., Maturation of dendritic cells is accompanied by rapid transcriptional silencing of class II transactivator (CIITA) expression. J. Exp. Med. 2001. 194: 379-391.
21. Martinez-Moczygemba, M. and Huston, D. P., Biology of common beta receptor-signaling cytokines: IL-3, IL-5, and GM-CSF. J. Allergy Clin. Immunol. 2003. 112: 653-665; quiz 666.
22. Pfitzner, E., Jahne, R.,Wissler,M., Stoecklin, E. and Groner, B., p300/CREB-binding protein enhances the prolactin-mediated transcriptional induction through direct interaction with the transactivation domain of Stat5, but does not participate in the Stat5-mediated suppression of the glucocorticoid response. Mol. Endocrinol. 1998. 12: 1582-1593.
23. Ye, S. K., Agata, Y., Lee, H. C., Kurooka, H., Kitamura, T., Shimizu, A., Honjo, T. and Ikuta, K., The IL-7 receptor controls the accessibility of the TCRgamma locus by Stat5 and histone acetylation. Immunity 2001. 15: 813-823.
24. Ehret, G. B., Reichenbach, P., Schindler, U., Horvath, C. M., Fritz, S., Nabholz, M. and Bucher, P., DNA binding specificity of different STAT proteins. Comparison of in vitro specificity with natural target sites. J. Biol. Chem. 2001. 276: 6675-6688.
25. Li, L., Li, S. P., Min, J. and Zheng, L., Hepatoma cells inhibit the differentiation and maturation of dendritic cells and increase the production of regulatory T cells. Immunol. Lett. 2007. 114: 38-45.
26. Ninomiya, T., Akbar, S. M., Masumoto, T., Horiike, N. and Onji, M., Dendritic cells with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma. J. Hepatol. 1999. 31: 323-331.
27. Cheng, P., Corzo, C. A., Luetteke, N., Yu, B., Nagaraj, S., Bui, M. M., Ortiz, M. et al., Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J. Exp. Med. 2008. 205: 2235-2249.
28. Liu, Y., Zeng, B., Zhang, Z., Zhang, Y. and Yang, R., B7-H1 on myeloid-derived suppressor cells in immune suppression by a mouse model of ovarian cancer. Clin. Immunol. 2008. 129: 471-481.
29. Ting, J. P. and Trowsdale, J., Genetic control of MHC class II expression. Cell 2002. 109: S21-S33.
30. LeibundGut-Landmann, S.,Waldburger, J. M., Krawczyk, M., Otten, L. A., Suter, T., Fontana, A., Acha-Orbea, H. and Reith, W., Mini-review: Specificity and expression of CIITA, the master regulator of MHC class II genes. Eur. J. Immunol. 2004. 34: 1513-1525.
31. Nickerson, K., Sisk, T. J., Inohara, N., Yee, C. S., Kennell, J., Cho, M. C., Yannie P. J., II et al., Dendritic cell-specific MHC class II transactivator contains a caspase recruitment domain that confers potent transactivation activity. J. Biol. Chem. 2001. 276: 19089-19093.
32. Yee, C. S., Yao, Y., Xu, Q., McCarthy, B., Sun-Lin, D., Tone, M.,Waldmann, H. and Chang, C. H., Enhanced production of IL-10 by dendritic cells deficient in CIITA. J. Immunol. 2005. 174: 1222-1229.
33. Novak, N., Bieber, T. and Katoh, N., Engagement of Fc epsilon RI on human monocytes induces the production of IL-10 and prevents their differentiation in dendritic cells. J. Immunol. 2001. 167: 797-804.
34. + blood monocytes, promotes the differentiation to mature macrophages and stimulates endocytosis of FITC-dextran. Adv. Exp. Med. Biol. 1997. 417: 323-327.
35. Ansel, K. M., Djuretic, I., Tanasa, B. and Rao, A., Regulation of Th2 differentiation and Il4 locus accessibility. Annu. Rev. Immunol. 2006. 24: 607-656.
36. Georgopoulos, K., Haematopoietic cell-fate decisions, chromatin regulation and ikaros. Nat. Rev. Immunol. 2002. 2: 162-174.
37. Jenuwein, T. and Allis, C. D., Translating the histone code. Science 2001. 293: 1074-1080.
38. Guthridge, M. A., Stomski, F. C., Thomas, D.,Woodcock, J. M., Bagley, C. J., Berndt, M. C. and Lopez, A. F., Mechanism of activation of the GM-CSF, IL-3, and IL-5 family of receptors. Stem Cells 1998. 16: 301-313.
39. Heppner, G. H., Dexter, D. L., DeNucci, T., Miller, F. R. and Calabresi, P., Heterogeneity in drug sensitivity among tumor cell subpopulations of a single mammary tumor. Cancer Res. 1978. 38: 3758-3763.
40. Murphy, G. P. and Hrushesky, W. J., A murine renal cell carcinoma. J. Natl. Cancer Inst. 1973. 50: 1013-1025.
41. Cannizzo F., Jr. and Broitman, S. A., Postpromotional effects of dietary marine or safflower oils on large bowel or pulmonary implants of CT-26 in mice. Cancer Res. 1989. 49: 4289-4294.
42. Inaba, K., Inaba, M., Romani, N., Aya, H., Deguchi, M., Ikehara, S., Muramatsu, S. and Steinman, R. M., Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 1992. 176: 1693-1702.
43. Lim, D. S., Kim, J. H., Lee, D. S., Yoon, C. H. and Bae, Y. S., DC immunotherapy is highly effective for the inhibition of tumor metastasis or recurrence, although it is not efficient for the eradication of established solid tumors. Cancer Immunol. Immunother. 2007. 56: 1817-1829.
44. Kamio, T., Toki, T., Kanezaki, R., Sasaki, S., Tandai, S., Terui, K., Ikebe, D. et al., B-cell-specific transcription factor BACH2 modifies the cytotoxic effects of anticancer drugs. Blood 2003. 102: 3317-3322.
45. Jang, J., Lim, D. S., Choi, Y. E., Jeong, Y., Yoo, S. A., Kim, W. U. and Bae, Y. S., MLN51 and GM-CSF involvement in the proliferation of fibroblast-like synoviocytes in the pathogenesis of rheumatoid arthritis. Arthritis Res. Ther. 2006. 8: R170.